Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.

Slides:



Advertisements
Similar presentations
Overview of Mental Health Medications for Children and Adolescents Module 2 Depressive Disorders 1.
Advertisements

Janey, Kevin, & Brittany Major Depression & Bipolar Disorder.
Management of Perinatal Depression Laurel Romer, M.D. Primary Care Conference October 11, 2006.
V.Sideri, C.Vliora, A.Daskalaki, P.Mexi-Bourna, K.Kleanthous, M.Soulioti, G. Kyrkou, N.Bournas, V.Papaevangelou 3 rd Pediatric Clinic of the University.
Discontinuation Syndrome Sue Henderson. Definition Cluster of symptoms that may occur in response to the reduction or cessation of any antidepressant,
Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
Obsessive Compulsive Disorder. Features of OCD Obsessions Obsessions –Recurrent and persistent thoughts; impulses; or images of violence, contamination,
Chapter 15 Psychological Disorders. Substance Abuse and Addictions Mental illness.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Methylphenidate Transdermal System (MTS): Safety Issues Robert Levin, M.D. Medical Officer Division of Psychiatry Products Center for Drug Evaluation and.
1 Neonatal Adverse Events Associated with in utero SSRI/SNRI Exposure Robert Levin, M.D. Medical Reviewer DNDP FDA.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 32 Antidepressants.
Elective Cesarean Delivery, Neonatal Intensive Care Unit Admission, and Neonatal Respiratory Distress 楊明智.
Cost-Conscious Care Presentation Follow-up Chest X-Ray in Patients Admitted for Community Acquired Pneumonia Huy Tran, PGY-2 12/12/2013.
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.
“Baby Blues” vs. Post-Partum Depression
SSRIs & Antidepressants
Postpartum Depression and Teens
for the Psychiatry Clerkship is proud to present And Now Here Is The Host... Insert Name Here.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
Sleep Disorders
Background Development of Anxiety Among Depressed Veterans After Antidepressant Usage Zhiguo Li, Paul Pfeiffer, Katherine Hoggatt, Kara Zivin, Karen Downing.
Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Strategies to Switch Antidepressants Brittany Parmentier, PharmD PGY2 Behavioral Care Resident Butler University/Community Health Network This speaker.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Antidepressants & Neuroleptics Lesson 20. Unipolar Depression n Major Depressive Disorder n Extreme sadness & despair l extent & duration important n.
Neurological Disorders. Psychological Disorders 10 million people suffer from depression.
Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.
PIPC ® Psychiatry In Primary Care Medications Robert K. Schneider, MD Departments of Psychiatry, Internal Medicine and Family Practice The Medical College.
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:
APPLIED PSYCHOLOGY LABORATORY East Tennessee State University Johnson City, Tennessee INTRODUCTION CONTACT:
Neonatal Antidepressant Effects Katherine L. Wisner, M.D., M.S. Professor of Psychiatry, Obstetrics and Gynecology and Reproductive Sciences and Epidemiology.
1 Antidepressants and Suicidality in Adults: Data Overview M. Lisa Jones MD, MPH Medical Reviewer Division of Psychiatry Products Psychopharmacologic Drugs.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.
Plans for Analysis of Patient Level Data for Pediatric Studies Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective.
Treating Pregnant Opioid Dependent Women: Examining Buprenorphine and Methadone Hendrée E. Jones, Ph.D. Associate Professor Department of Psychiatry and.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
Zoloft By Christine Daniel. Some information about Zoloft… Zoloft is the brand name for Sertraline. Sertraline belongs to a group of medications known.
Good Pharmacovigilance Practices
Effectiveness of Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitors in Adolescents with Depression Megan Boose, PA-S Evidence Based.
ANGELS Update Antidepressants in Pregnancy Linda L.M. Worley, MD, Associate Professor UAMS, Departments of Psychiatry & OB/GYN.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.
Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.
Topical Corticosteroid Adverse Events in Pediatric Patients Analysis of Postmarketing Reports Pediatric Advisory Subcommittee of the Anti-Infective Drugs.
1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.
Kamelia Mirdamadi BSc. Pina Bozzo BSc. Gideon Koren MD, FRCPC The Motherisk Program, Hospital for Sick Children Mental health disorders such as schizophrenia.
Depression and Aging Aging Q 3 William P. Moran, MD, MS Medical University of South Carolina October 31, 2012.
TM Influenza Vaccine Safety in Children: Data from VAERS John Iskander MD MPH Gina Mootrey DO MPH Penina Haber MPH Roseanne English-Bullard BS.
Specific issues in drug use and pregnancy. Pregnant women who use drugs (RCOG, 2010) One of the challenges for pregnant women who use drugs is that they.
Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children Hilary K. Brown, PhD; Joel G. Ray, MD, MSc,
By dr.safeyya alchalabi
Obsessive Compulsive Disorder (OCD) Abdulaziz S. Alsultan
Neonatal Abstinence Syndrome: An emerging issue for Part C systems?
Birdsong Conference 3/27/11 Marcia L. Buck, Pharm.D.
Mood Disorders Emotional disturbances that disrupt physical, perceptual, social, and thought processes.
Svetlana Skurtveit, Ingunn Olea Lund, Jørgen G
Duloxetine Flavio Guzman, MD.
Depression in Older Adults Depression is common in older adults, and especially prevalent in older adults with chronic illnesses EPIDEMIOLOGY OF DEPRESSION.
Sertraline In this section we’ll discuss the most relevant aspects of sertraline.
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Prescribing SGAs During Pregnancy
Antidepressant Discontinuation Syndrome
Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.
Presentation transcript:

Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator Division of Drug Risk Evaluation Office of Drug Safety

Pediatric AC 6/9/042 Outline FDA Adverse Event Reporting system (AERS) –Contents –Limitations –Value Office of Drug Safety adverse event reviews Review of neonatal withdrawal syndrome after in utero exposure to serotonin reuptake inhibitors (SRIs) Conclusions

Pediatric AC 6/9/043 Adverse Event Reporting System (AERS) Contains > 3 million reports of suspected adverse drug and biological product events Sources include healthcare professionals, consumers, medical literature, postmarketing clinical studies No reporting requirements for healthcare professionals Reporting requirements for manufacturers vary with event severity and expectedness Expectedness is determined by drug labeling

Pediatric AC 6/9/044 AERS data limitations Voluntary; therefore, underreporting Estimated or no denominators available – usage during pregnancy is not available Cannot accurately determine incidence rate Information is often incomplete Reporting biases differ between drugs Cannot confirm that a drug caused an adverse event or that drugs differ in relatedness to an adverse event

Pediatric AC 6/9/045 Value of AERS data Discovery of previously unknown adverse drug events –Adverse events too rare to be seen in trials –Adverse events in population not exposed to drug in trials (pregnant women) –Greater severity than adverse events seen in trials Triggers further investigation – call for follow- up, review available data, request study

Pediatric AC 6/9/046 Office of Drug Safety Reviews Monitor adverse event reports as they are entered into AERS database For selected cases, contact reporters for additional information Search AERS and medical literature Evaluate reports and develop case series Office of Drug Safety reports findings to new drug review divisions and recommends action

Pediatric AC 6/9/047 AERS reports of neonatal withdrawal with Serotonin Reuptake Inhibitors SRIs citalopram (Celexa), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), sertraline (Zoloft), venlafaxine (Effexor) SRI discontinuation syndrome known adverse event in adults Review of reports with MedDRA code “drug withdrawal neonatal” suggested neurological, neuromuscular, autonomic events AERS search broadened

Pediatric AC 6/9/048 AERS search strategies Either MedDRA High Level Group Term: “neonatal neurological system disorders” OR Preferred Term: “drug withdrawal syndrome neonatal” A large group of MedDRA terms encompassing various neurological, neuromuscular, and autonomic system adverse events AND age 0 to 3 months Both MedDRA Preferred Terms: “complications of maternal exposure to therapeutic drugs” AND “drug withdrawal syndrome”

Pediatric AC 6/9/049 Neonatal withdrawal syndrome case definition applied 1 EITHER all four of the following: Maternal SRI use at birth Not attributable to other cause Onset hours to days after birth Resolved in days to weeks OR Reported as SRI withdrawal 1 Schatzberg AF, et al. Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 1997;58[suppl 7]5-10.

AERS case counts Drug (t½ hours)2001Met definition Venlafaxine (5-11)22335 Fluvoxamine (15)929 Paroxetine (21) Sertraline (26)33812 Citalopram (35)12518 Fluoxetine (4-16 days)56422

Pediatric AC 6/9/0411 Excluded cases: fluoxetine (N=52) 12 exposure to other drugs assoc with withdrawal 10 adverse event present at birth 8 timing of adverse event vs. birth unclear 8 adverse event not consistent with withdrawal 6 fluoxetine discontinued early in pregnancy 3 adverse event persisting months after birth 2 adverse event occurred in utero 1 adverse event after discontinue breastfeeding 1 timing of fluoxetine use unclear 1 admin of fluoxetine not relieve symptoms

Pediatric AC 6/9/0412 Maternal information 56 mothers, 1 twin pregnancy, 57 neonates Ages unknown in large majority of cases Diagnoses for SRI use: unknown (28), depression (21), schizophrenia (3), anxiety (2) SRI dosage within labeled recommendations except for venlafaxine 450 mg/day (1) Confounders: alcohol occasional (4), cigarettes (7), marijuana (2)

Pediatric AC 6/9/0413 Neonate information (N=57) Gestation ≥ 37 wks (30), < 37 wks (5) Gender: male (25), female (17) Birth weight: range 860 grams – 4.23 kg, mean 3.04 kg, median 3.12 kg (28) Apgar scores: 1 minute range 1-9, mean 7.4, median 8 (20) 5 minute range 6-10, mean 8.6, median 9 (19) 10 minute range 6-10, mean 9, median 9 (9)

Adverse event information (N=57) Drug T1/2 hours Median time to onset (N) Median duration (N) Venlafaxine hours (1)2 days (1) Fluvoxamine 15 hours-2 days (2)5 days (1) Paroxetine hours (19)1.5-2 wks (17) Sertraline hours (6)1 day (7) Citalopram hours (5)7 days (5) Fluoxetine 4-16 days 1.5 days (4)1 week (3)

Reported signs of SRI neonatal withdrawal not mutually exclusive (N) CNSNeuromuscularGI/autonomic irritability (20)hypertonia (17)trouble feed (13) jitteriness (14)tremor (13)vomiting (4) agitation (8)seizures (8)tachypnea (7) crying (5)posturing (6)trouble breathe (5) screaming (4)hypotonia (4)resp distress (3) high-pitch cry (3)jerkiness (3)hypothermia (3) EEG abnorm (2)hyperreflexia (3)shivering (3)

Pediatric AC 6/9/0416 Labeled signs and symptoms of discontinuation in adults dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania.

Pediatric AC 6/9/0417 Treatments and outcomes (N=57) Treatments [not mutually exclusive] –Hospitalization (37) –Phenobarbital (9) or benzodiazepine (2) –Oxygen/ventilation (5) –Antibiotic (3) –Tube feeding (4) –Intravenous fluids (3) Outcomes: resolved (31), improved (12), ongoing (3), unknown (11)

Pediatric AC 6/9/0418 Conclusions AERS data support the existence of a withdrawal syndrome in neonates exposed to SRI medications in utero at the end of pregnancy. Reports of cases possibly related to drug have been received for citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine, suggesting a class effect.

Pediatric AC 6/9/0419 Conclusions Excitatory nervous and neuromuscular events are the most frequently reported signs of neonatal SRI withdrawal. Breathing and feeding difficulties have required supportive care. Healthcare providers should be made aware that adverse events may be seen in neonates exposed to SRI medications just prior to birth.

Pediatric AC 6/9/0420 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator Division of Drug Risk Evaluation Office of Drug Safety